sb 202190 has been researched along with Diabetes Mellitus, Type 1 in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Purves, T | 1 |
| Middlemas, A | 1 |
| Agthong, S | 1 |
| Jude, EB | 1 |
| Boulton, AJ | 1 |
| Fernyhough, P | 1 |
| Tomlinson, DR | 1 |
1 other study available for sb 202190 and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy.
Topics: Animals; Butadienes; Cell Survival; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Melli | 2001 |